Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 691 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Primary Headache Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

Muscle Treatment for Management of Pain & Disability in Tension-type Headache

NCT01244555
View directory record Official record
Conditions
Tension-type Headache
Interventions
ultrasound, massage
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 59 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Efficacy of Behavioral Insomnia Treatment for Chronic Migraine

NCT01314651
View directory record Official record
Conditions
Chronic Migraine, Insomnia
Interventions
Stimulus Control and Sleep Restriction, Lifestyle Modification
Behavioral
Lead sponsor
Daniel Riche
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 14, 2026, 8:59 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults

NCT01981499
View directory record Official record
Conditions
Migraine
Interventions
PF-05180999, Placebo, 120 mg MR PF-05180999, 360 mg MR PF-05180999, 10 mg cetirizine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Intramuscular Ropivacaine Injections for Treatment of Pediatric Headache

NCT00680823
View directory record Official record
Conditions
Headache, Migraine
Interventions
Ropivacaine, Normal saline
Drug
Lead sponsor
Robert Hickey
Other
Eligibility
7 Years to 17 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Oct 14, 2026, 8:59 AM EDT
Not yet recruiting Not applicable Interventional

Can a Specific OMT Protocol Influence Patient Pain and Associated Analgesia Use for Primary Headache Disorders?

NCT06546462
View directory record Official record
Conditions
Headache Disorders, Headache, Analgesia, Opioid Use, Osteopathy
Interventions
Osteopathic Manipulative Treatment (OMT), Sham Light touch arm
Other
Lead sponsor
New York Institute of Technology
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Old Westbury, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

Study Evaluated the Effectiveness of Milnacipran to Reduce Pain Levels in Individuals With Chronic Migraine

NCT01393522
View directory record Official record
Conditions
Chronic Migraine
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Timothy Smith
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
St Louis, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2022 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)

NCT00387881
View directory record Official record
Conditions
Migraine, Without Aura
Interventions
sumatriptan succinate / naproxen sodium, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
679 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
70
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 58 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2016 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Nitrous Oxide for Acute Migraine Pain in the Emergency Room (ED)

NCT01287052
View directory record Official record
Conditions
Migraine, Pain
Interventions
Nitrous Oxide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
8 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist

NCT04294147
View directory record Official record
Conditions
Migraine
Interventions
Galcanezumab, Erenumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Los Angeles, California • Newport Beach, California • Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 14, 2026, 8:59 AM EDT
Recruiting Not applicable Interventional

MMA Embolization for Refractory Chronic Migraine

NCT06735833
View directory record Official record
Conditions
Migraine Disorders
Interventions
Middle Meningeal Artery embolization
Device
Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Walnut Creek, California • Hartford, Connecticut • Buffalo, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Low-dose Propofol for Pediatric Migraine

NCT01604785
View directory record Official record
Conditions
Migraine Headache
Interventions
Propofol, Standard Treatment
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
7 Years to 18 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional Results available

A Clinical Study Examining the Safety and Effectiveness of a New Medication (Keppra®) for the Prevention of Migraine Headaches

NCT00203216
View directory record Official record
Conditions
Migraine
Interventions
levetiracetam, Transcranial Magnetic Stimulation
Drug · Procedure
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2011 · Synced Oct 14, 2026, 8:59 AM EDT
Not yet recruiting Phase 3 Interventional

0.5% Bupivacaine Lower Cervical Intramuscular Injection vs IV Medications for Headache Treatment

NCT06937385
View directory record Official record
Conditions
Headache, Migraine, Tension Headache, Occipital Neuralgia
Interventions
0.5% Bupivacaine HCl, standard IV treatment for headache
Drug
Lead sponsor
HCA Florida North Florida Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 14, 2026, 8:59 AM EDT
Completed No phase listed Observational

Healthcare Costs and Resource Utilization in Aimovig Migraine Patients: a Retrospective Study Using United States Claims Data

NCT05177406
View directory record Official record
Conditions
Migraine
Interventions
Aimovig
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2022 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Blood Flow Within Active Myofascial Trigger Points Following Massage

NCT02389140
View directory record Official record
Conditions
Myofascial Pain, Tension-type Headache
Interventions
Trigger point release, Ultrasound
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 49 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Results available

Greater Occipital Nerve Block Versus Metoclopramide

NCT03269435
View directory record Official record
Conditions
Migraine
Interventions
Greater occipital nerve block with bupivacaine, Metoclopramide
Procedure · Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 14, 2026, 8:59 AM EDT
Completed No phase listed Observational Results available

Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)

NCT01257880
View directory record Official record
Conditions
Migraine With Aura, Patent Foramen Ovale
Interventions
Not listed
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2011 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Not applicable Interventional

Exploring the Effect of the Transcendental Meditation® Technique on Migraine Frequency, Intensity, and Functionality: A Single-Arm Study

NCT06695156
View directory record Official record
Conditions
Migraine, Migraine With or Without Aura
Interventions
Meditation
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults

NCT00573170
View directory record Official record
Conditions
Migraine Disorders, Migraine, Acute
Interventions
TREXIMET®, Butalbital-containing Combination Medications (BCM), placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2010 · Synced Oct 14, 2026, 8:59 AM EDT
Terminated Phase 4 Interventional Results available

Real World Effectiveness of Eptinezumab in Participants With Migraine

NCT05284019
View directory record Official record
Conditions
Migraine
Interventions
Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 14, 2026, 8:59 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 14, 2026, 8:59 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Headache Ear Auditory Dizziness Sinus (HEADS) Registry

NCT07754266
View directory record Official record
Conditions
Headache Disorders, Dizziness, Vestibular Diseases, Sinus Disease, Vestibular Disorder, Migraine Disorders, Headache, Migraine, Facial Pain
Interventions
Not listed
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
1
States / cities
North Kingstown, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 8:59 AM EDT
Terminated Phase 3 Interventional

ESCAPE Migraine Trial

NCT00267371
View directory record Official record
Conditions
Migraine Disorders, Heart Septal Defects, Atrial
Interventions
PFO Closure with Premere investigational device., Medical management/current medications per standard of care by personal physician.
Device · Drug
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
37
States / cities
Scottsdale, Arizona • Newport Beach, California • Sacramento, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 14, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

NCT05216263
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Hoover, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 14, 2026, 8:59 AM EDT